Preclinical comparison of [177Lu]Lu-rhPSMA-10.1 and [177Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Preclinical comparison of [177Lu]Lu-rhPSMA-10.1 and [177Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies ; volume:9 ; number:1 ; day:26 ; month:2 ; year:2024 ; pages:1-14 ; date:12.2024
EJNMMI radiopharmacy and chemistry ; 9, Heft 1 (26.2.2024), 1-14, 12.2024
- Urheber
-
Wurzer, Alexander
Rose, Francesco De
Fischer, Sebastian
Schwaiger, Markus
Weber, Wolfgang
Nekolla, Stephan
Wester, Hans-Jürgen
Eiber, Matthias
D’Alessandria, Calogero
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s41181-024-00246-2
- URN
-
urn:nbn:de:101:1-2405021313212.896169206004
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:49 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Wurzer, Alexander
- Rose, Francesco De
- Fischer, Sebastian
- Schwaiger, Markus
- Weber, Wolfgang
- Nekolla, Stephan
- Wester, Hans-Jürgen
- Eiber, Matthias
- D’Alessandria, Calogero
- SpringerLink (Online service)
Ähnliche Objekte (12)
![Experience of rescue therapy with [177Lu]Lu-rhPSMA-10.1 in patients with primary or acquired resistance to [177Lu]Lu-PSMA-I&T](/assets/placeholder/searchResultMediaUnknown.png)
Experience of rescue therapy with [177Lu]Lu-rhPSMA-10.1 in patients with primary or acquired resistance to [177Lu]Lu-PSMA-I&T
Urinary excretion kinetics of [177Lu]Lu-PSMA-617
Dual Radionuclide Therapy: The Synergistic Effects of [161Tb]Tb-PSMA and [177Lu]Lu-PSMA in Advanced Prostate Cancer Post [177Lu]Lu-PSMA Failure
Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry
Improved quality control of [177Lu]Lu-PSMA I&T
Correction to: Dual Radionuclide Therapy: The Synergistic Effects of [161Tb]Tb-PSMA and [177Lu]Lu-PSMA in Advanced Prostate Cancer Post [177Lu]Lu-PSMA Failure
Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
EP-0565 Safety and efficacy of [177Lu]Lu-rhPSMA-10.1 re-challenge therapy in progressive mCRPC after [177Lu] Lu-PSMA I&T therapy: preliminary results [Abstract]
Improved therapeutic index with the novel PSMA-ligand 177Lu-rhPSMA-10.1 compared to 177Lu-PSMA I&T - an intrapatient comparison [Abstract]
177Lu-rhPSMA-10.1 induces tumor response in a patient with mCRPC after PSMA-directed radioligand therapy with 177Lu-PSMA-I AND T
Biodistribution and dosimetry for combined [177Lu]Lu-PSMA-I&T/[225Ac]Ac-PSMA-I&T therapy using multi-isotope quantitative SPECT imaging
[177Lu]Lu-PSMA-617 salivary gland uptake characterized by quantitative in vitro autoradiography
Experience of rescue therapy with [177Lu]Lu-rhPSMA-10.1 in patients with primary or acquired resistance to [177Lu]Lu-PSMA-I&T
Urinary excretion kinetics of [177Lu]Lu-PSMA-617
Dual Radionuclide Therapy: The Synergistic Effects of [161Tb]Tb-PSMA and [177Lu]Lu-PSMA in Advanced Prostate Cancer Post [177Lu]Lu-PSMA Failure
Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry
Improved quality control of [177Lu]Lu-PSMA I&T
Correction to: Dual Radionuclide Therapy: The Synergistic Effects of [161Tb]Tb-PSMA and [177Lu]Lu-PSMA in Advanced Prostate Cancer Post [177Lu]Lu-PSMA Failure
Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
EP-0565 Safety and efficacy of [177Lu]Lu-rhPSMA-10.1 re-challenge therapy in progressive mCRPC after [177Lu] Lu-PSMA I&T therapy: preliminary results [Abstract]
Improved therapeutic index with the novel PSMA-ligand 177Lu-rhPSMA-10.1 compared to 177Lu-PSMA I&T - an intrapatient comparison [Abstract]
177Lu-rhPSMA-10.1 induces tumor response in a patient with mCRPC after PSMA-directed radioligand therapy with 177Lu-PSMA-I AND T
Biodistribution and dosimetry for combined [177Lu]Lu-PSMA-I&T/[225Ac]Ac-PSMA-I&T therapy using multi-isotope quantitative SPECT imaging
[177Lu]Lu-PSMA-617 salivary gland uptake characterized by quantitative in vitro autoradiography
Experience of rescue therapy with [177Lu]Lu-rhPSMA-10.1 in patients with primary or acquired resistance to [177Lu]Lu-PSMA-I&T
Urinary excretion kinetics of [177Lu]Lu-PSMA-617
Dual Radionuclide Therapy: The Synergistic Effects of [161Tb]Tb-PSMA and [177Lu]Lu-PSMA in Advanced Prostate Cancer Post [177Lu]Lu-PSMA Failure
Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry
Improved quality control of [177Lu]Lu-PSMA I&T
Correction to: Dual Radionuclide Therapy: The Synergistic Effects of [161Tb]Tb-PSMA and [177Lu]Lu-PSMA in Advanced Prostate Cancer Post [177Lu]Lu-PSMA Failure
Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
EP-0565 Safety and efficacy of [177Lu]Lu-rhPSMA-10.1 re-challenge therapy in progressive mCRPC after [177Lu] Lu-PSMA I&T therapy: preliminary results [Abstract]
Improved therapeutic index with the novel PSMA-ligand 177Lu-rhPSMA-10.1 compared to 177Lu-PSMA I&T - an intrapatient comparison [Abstract]
177Lu-rhPSMA-10.1 induces tumor response in a patient with mCRPC after PSMA-directed radioligand therapy with 177Lu-PSMA-I AND T
Biodistribution and dosimetry for combined [177Lu]Lu-PSMA-I&T/[225Ac]Ac-PSMA-I&T therapy using multi-isotope quantitative SPECT imaging